Connection
Bradley Haverkos to Antineoplastic Agents, Immunological
This is a "connection" page, showing publications Bradley Haverkos has written about Antineoplastic Agents, Immunological.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.249 |
|
|
|
-
Haverkos BM, Chang C, Ristuccia R, Chang Y, Friderici J, DeGutis IS, Rozati S. Treatment utilization and outcomes in patients with mycosis fungoides and Sézary syndrome receiving mogamulizumab in community and academic practice in the United States clinical practice. Leuk Lymphoma. 2026 Aug; 67(10):2035-2047.
Score: 0.795
-
Herbaux C, Merryman R, Devine S, Armand P, Houot R, Morschhauser F, Haverkos B. Recommendations for managing PD-1 blockade in the context of allogeneic HCT in Hodgkin lymphoma: taming a necessary evil. Blood. 2018 07 05; 132(1):9-16.
Score: 0.453